Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC). The number of chronically infected persons worldwide is estimated to be about 160 million, but most are unaware of their infection.
The implementation of extended criteria for screening for HCV is a subject of major debate among different stakeholders. Clinical care for patients with HCV-related liver disease has advanced considerably during the last two decades, thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention.
An update of the HCV EASL recommendations will be presented in Paris, France on Thursday 22 September 2016 to open the EASL/AASLD Special Conference.
If your research involves Hepatitis C register now to the Special Conference to take part and be the first to access the revised HCV recommendations!